Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Mary Buckwalter"'
Autor:
Erik P. Sandefer, Patrick Martin, Walter J. Doll, Mary Buckwalter, James Ermer, Brian Diehl, Kerry Dennis, Richard C. Page, Mary B. Haffey
Publikováno v:
Clinical Drug Investigation. 31:357-370
Data on pharmacokinetic parameters of the prodrug stimulant lisdexamfetamine dimesylate via alternate routes of administration are limited. The pharmacokinetics of d-amphetamine derived from lisdexamfetamine dimesylate after single oral (PO) versus i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5b430c3db837c91bd56c282a991c61d
https://doi.org/10.2165/11588190-000000000-00000
https://doi.org/10.2165/11588190-000000000-00000
Autor:
Robert Homolka, James Ermer, Mary Buckwalter, Patrick Martin, Jaideep Purkayastha, Benno Roesch
Publikováno v:
The Journal of Clinical Pharmacology. 50:1001-1010
The pharmacokinetics of lisdexamfetamine dimesylate, a long-acting prodrug stimulant, and its active moiety, d-amphetamine, including dose-proportionality and variability, were assessed in 20 healthy adults. Subjects received a single dose, sequentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6208da36d9f02240d3f73fb59268bd5c
https://doi.org/10.1177/0091270009357346
https://doi.org/10.1177/0091270009357346
Autor:
Kenneth C. Lasseter, James Ermer, Robert Homolka, Pinggao Zhang, Mary Buckwalter, Patrick Martin, Mary B. Haffey
Publikováno v:
Postgraduate Medicine. 121:11-19
To evaluate the pharmacokinetics of lisdexamfetamine dimesylate (LDX), a long-acting prodrug stimulant, and mixed amphetamine salts extended-release (MAS XR), alone or with omeprazole, a proton pump inhibitor (PPI).This open-label, randomized, 4-peri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a92aa997f103f2266a8bec0478c65d85
https://doi.org/10.3810/pgm.2009.09.2048
https://doi.org/10.3810/pgm.2009.09.2048
Publikováno v:
The Journal of Clinical Pharmacology. 49:465-476
Three open-label studies assessed the safety, tolerability, and pharmacokinetics of intravenous dalbavancin in patients with hepatic or renal impairment, including patients with end-stage renal disease (ESRD) receiving dialysis. In each study, 4 to 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ef30ff13fa6dba5d52551ecc649ede
https://doi.org/10.1177/0091270008330162
https://doi.org/10.1177/0091270008330162
Publikováno v:
Journal of Antimicrobial Chemotherapy. 60:681-684
Objectives Dalbavancin is a novel lipoglycopeptide antibiotic in development for the treatment of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria. The aim of the present study was to assess the penetration of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8efb24961cfae3f3ea01cb57474585a8
https://doi.org/10.1093/jac/dkm263
https://doi.org/10.1093/jac/dkm263
Autor:
Mary Buckwalter, James A. Dowell
Publikováno v:
The Journal of Clinical Pharmacology. 45:1279-1287
Dalbavancin is a lipoglycopeptide antibiotic in clinical development as a once-weekly treatment for serious infections. A total of 532 patients, consisting of 502 patients with skin and soft tissue infections requiring parenteral therapy and 30 patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d35a88433f661916d3f4e63369ad6fb1
https://doi.org/10.1177/0091270005280378
https://doi.org/10.1177/0091270005280378
Publikováno v:
The Journal of Clinical Pharmacology. 45:246-256
This study was performed to estimate the population pharmacokinetic (PK) parameters of etanercept in pediatric juvenile rheumatoid arthritis (JRA) patients and to compare the steady-state time-concentration profiles between etanercept 0.8-mg/kg once-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4488d6d877a210f7eda8d90fb0d0be28
https://doi.org/10.1177/0091270004271945
https://doi.org/10.1177/0091270004271945
Autor:
Alain Patat, Honghui Zhou, Mary Buckwalter, Virginia Parks, Deborah Metzger, Joan M. Korth-Bradley
Publikováno v:
The Journal of Clinical Pharmacology. 44:543-550
Etanercept, a soluble recombinant human tumor necrosis factor receptor (TNFr) fusion protein, is effective and well tolerated in the treatment of rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), psoriatic arthritis (PsA), and ankylosin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48dc843999b56abcc85284208b4a121c
https://doi.org/10.1177/0091270004264164
https://doi.org/10.1177/0091270004264164
Publikováno v:
Journal of clinical psychopharmacology. 30(5)
This was a 1-month, multicenter, open-label, randomized study to determine single- and multiple-dose pharmacokinetics of d,l-methylphenidate (MPH) after MPH transdermal system (MTS) and osmotic-release oral system MPH (OROS MPH) dosing in children (6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::365ac9eca1b8ecf627fad22ae3d20beb
https://pubmed.ncbi.nlm.nih.gov/20814325
https://pubmed.ncbi.nlm.nih.gov/20814325
Publikováno v:
Journal of clinical pharmacology. 48(9)
Dalbavancin is a novel glycopeptide with a 2-dose, once-weekly dosing regimen that is being developed for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Monte Carlo simulations were performed for dal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0458354490c83cd692300feb4cacd56a
https://pubmed.ncbi.nlm.nih.gov/18633123
https://pubmed.ncbi.nlm.nih.gov/18633123